Serial 14-3-3η testing: informing RA flare and joint damage risk as you treat-to-target
Vancouver, BC – April 18, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and Japan will present data on 14-3-3η blood testing in Rheumatoid Arthritis (RA).
“Studies to be presented at JCR continue to fortify the clinical usefulness of 14-3-3η testing on its own, and in conjunction with other markers to identify patients whom are less likely to flare following discontinuation of therapy” says Professor Yoshiya Tanaka, Professor & Chairman of The First Department of Internal Medicine, School of Medicine University of Occupational & Environmental Health, Japan. He adds, “14-3-3η is a pro-inflammatory, modifiable, marker that is independent of acute phase reactants and reflects active joint damage processes that are underway. This makes it an ideal marker to track over time to optimize RA treat-to-target strategies to improve clinical and radiographic outcomes. In the coming years, I expect that 14-3-3η testing will become as routine for joint damage risk monitoring as anti-CCP is for RA classification and CRP for informing inflammation”.
List of 14-3-3η JCR 2017 Conference Proceedings
| Title & Author | Date & Location |
|---|---|
| Prediction of Joint Damage Progression and Flare after Adalimumab Discontinuation by Serum 14-3-3η Levels in Patients with RA (post hoc analysis of HONOR study) Authors: Yoshiya Tanaka, Shintaro Hirata, Kentaro Hanami and Anthony Marotta Poster Number: P1-003 |
Apr 20, 13:20 – 14:40 Poster hall |
| Serum 14-3-3η Levels Predicts Responsiveness to Tocilizumab in Patients with RA Authors: Yoshiya Tanaka, Shintaro Hirata, Kentaro Hanami and Anthony Marotta Oral Presentation: W27-2 |
Apr 21, 9:20 – 10:20 Room 8 (401 + 402 + 403) |
| Profiling 14-3-3η in Human Primary Cell Based BioMAP® Disease Models a Unique Pro-Inflammatory Phenotypic Signature Consistent with Rheumatoid Arthritis (RA)-Inflammation Biology Authors: Yoshiya Tanaka, Alison O’Mahony, Ellen Berg, Walter Maksymowych, Yuan Gui and Anthony Marotta Oral Presentation: W48-1 |
Apr 21, 15:10 – 16:10 Room 9 (404 +405 + 406) |
For more information on JOINTstat™ (14-3-3η) during the conference, please visit the Medical and Biological Laboratories (MBL) exhibit booth #8.
Global Access to JOINTstat™ (14-3-3η) for Transformation of RA Patient Management
Follow this webinar link to learn how JOINTstat™ (14-3-3η) is helping clinicians achieve treat-to-target strategies to optimize RA patient outcomes. LifeLabs, in collaboration with Dr. Gilles Boire, MD, MSc, FRCPC, Dr. Kam Shojania, MD, FRCPC, and Dr. Anthony Marotta, PhD, hosted a webinar education program titled “Early RA Detection & Monitoring of Joint Damage with 14-3-3η”. The session describes how JOINTstat™ testing assists with early RA referral and joint damage risk monitoring to target radiographic remission. Presenters highlighted the benefits of JOINTstat™ testing along the RA continuum of care and presented patient case studies demonstrating how JOINTstat™ informs clinical decision-making in day-to-day care to transform patient management.
Under the registered trade name JOINTstat™, the 14-3-3η test is available in Canada through LifeLabs, is distributed in Japan by MBL (Medical & Biological Laboratories), available for clinical use in Europe, Australia and in the US as an LDT through Labcorp (Laboratory Corporation of America) and RDL Reference Laboratory.
Comments are closed.